Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals
Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1-3 and individuals with COVID-19 have symptoms that can be asymptomatic, mild, moderate or severe4,5. In the early phase of infection, T- and B-cell counts are substantially decreased6,7; however, IgM8-11 and IgG12-14 are detectable within 14 d after symptom onset. In COVID-19-convalescent individuals, spike-specific neutralizing antibodies are variable3,15,16. No specific drug or vaccine is available for COVID-19 at the time of writing; however, patients benefit from treatment with serum from COVID-19-convalescent individuals17,18. Nevertheless, antibody responses and cross-reactivity with other coronaviruses in COVID-19-convalescent individuals are largely unknown. Here, we show that the majority of COVID-19-convalescent individuals maintained SARS-CoV-2 spike S1- and S2-specific antibodies with neutralizing activity against the SARS-CoV-2 pseudotyped virus, and that some of the antibodies cross-neutralized SARS-CoV, Middle East respiratory syndrome coronavirus or both pseudotyped viruses. Convalescent individuals who experienced severe COVID-19 showed higher neutralizing antibody titres, a faster increase in lymphocyte counts and a higher frequency of CXCR3+ T follicular help (TFH) cells compared with COVID-19-convalescent individuals who experienced non-severe disease. Circulating TFH cells were spike specific and functional, and the frequencies of CXCR3+ TFH cells were positively associated with neutralizing antibody titres in COVID-19-convalescent individuals. No individuals had detectable autoantibodies. These findings provide insights into neutralizing antibody responses in COVID-19-convalescent individuals and facilitate the treatment and vaccine development for SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Nature microbiology - 6(2021), 1 vom: 16. Jan., Seite 51-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Jian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 13.01.2021 Date Revised 22.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41564-020-00824-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317671782 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317671782 | ||
| 003 | DE-627 | ||
| 005 | 20231225163743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41564-020-00824-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317671782 | ||
| 035 | |a (NLM)33199863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Jian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2021 | ||
| 500 | |a Date Revised 22.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1-3 and individuals with COVID-19 have symptoms that can be asymptomatic, mild, moderate or severe4,5. In the early phase of infection, T- and B-cell counts are substantially decreased6,7; however, IgM8-11 and IgG12-14 are detectable within 14 d after symptom onset. In COVID-19-convalescent individuals, spike-specific neutralizing antibodies are variable3,15,16. No specific drug or vaccine is available for COVID-19 at the time of writing; however, patients benefit from treatment with serum from COVID-19-convalescent individuals17,18. Nevertheless, antibody responses and cross-reactivity with other coronaviruses in COVID-19-convalescent individuals are largely unknown. Here, we show that the majority of COVID-19-convalescent individuals maintained SARS-CoV-2 spike S1- and S2-specific antibodies with neutralizing activity against the SARS-CoV-2 pseudotyped virus, and that some of the antibodies cross-neutralized SARS-CoV, Middle East respiratory syndrome coronavirus or both pseudotyped viruses. Convalescent individuals who experienced severe COVID-19 showed higher neutralizing antibody titres, a faster increase in lymphocyte counts and a higher frequency of CXCR3+ T follicular help (TFH) cells compared with COVID-19-convalescent individuals who experienced non-severe disease. Circulating TFH cells were spike specific and functional, and the frequencies of CXCR3+ TFH cells were positively associated with neutralizing antibody titres in COVID-19-convalescent individuals. No individuals had detectable autoantibodies. These findings provide insights into neutralizing antibody responses in COVID-19-convalescent individuals and facilitate the treatment and vaccine development for SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
| 650 | 7 | |a CXCR3 protein, human |2 NLM | |
| 650 | 7 | |a Receptors, CXCR3 |2 NLM | |
| 700 | 1 | |a Wu, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ziyan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qijie |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jiajing |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Yabin |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Mincheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Tiantian |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Danhong |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Weijin |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Wangyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Dixian |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Dongzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhijian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guicheng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Renbin |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yingbiao |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiangping |e verfasserin |4 aut | |
| 700 | 1 | |a He, Shuangyan |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Yunfan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jianghua |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Weilang |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Zhongyi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Haifu |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Qingting |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yi-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Youchun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wenpei |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Xiaowang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature microbiology |d 2016 |g 6(2021), 1 vom: 16. Jan., Seite 51-58 |w (DE-627)NLM257483241 |x 2058-5276 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:1 |g day:16 |g month:01 |g pages:51-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41564-020-00824-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 1 |b 16 |c 01 |h 51-58 | ||